Helen Kim

Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY.

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

TRF Pharma, Inc. develops pharmaceutical products. It specializes in the fields of hematology and oncology. The firm's services include developing therapies to treat diseases related to aberrant cell adhesion and endothelial walls. The company was founded by Stephen H. Embury and Neil Matsui in 2002 and is headquartered in Burlingame, CA.

ForSight VISION4, Inc. develops novel drug delivery therapies for treatment of retinal diseases. The company was founded on June 26, 009 and is headquartered in Menlo Park, CA.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX.

Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA.

The Gordon and Betty Moore Foundation operate as a grantmaking organization works locally through its San Francisco Bay Area Program. It seeks to make a contribution to the quality of life in the bay area through targeted support in three areas: land protection, science and technology museums and the Betty Irene Moore Nursing Initiative. The company was founded by Gordon and Betty Moore in 2000 and is headquartered in San Francisco, CA.

The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco.

WCCT Global, Inc. operates as a pharmaceutical contract research organization. It offers CPU research sites and services, Medelis CRO services, therapeutic expertise, and clinical support services. The firm serves the pharmaceutical, biotechnology, and medical device industries. The company was founded by Kenneth T. Kim in 1998 and is headquartered in Costa Mesa, CA.

Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA.

Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX.

VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts.

PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA.

A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA.

Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY.

IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish.

Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020.

InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia.